Ximelagatran (X), 36 mg or 24 mg twice daily, v warfarin after total knee replacement at 7–12 days*
| Outcomes | X dose | Event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Composite primary endpoint = venous thromboembolism, pulmonary embolism, and all cause mortality. Abbreviations defined in glossary; NNT, NNH, and CI calculated from data in article. | ||||
| Composite primary endpoint | 36 mg | 20.3% v 27.6% | 26% (9.9 to 40) | 14 (9 to 40) |
| 24 mg | 24.9% v 27.6% | 9.8% (−8.8 to 25) | Not significant | |
| RRI (CI) | NNH | |||
| Major bleeding | 36 mg | 0.8% v 0.7% | 18% (−61 to 264) | Not significant |
| 24 mg | 0.8% v0.7% | 20% (−61 to 270) | Not significant | |